| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2001;37:1199.)
© 2001 American Heart Association, Inc.
Review Article |
Gender Differences in the Regulation of Blood Pressure
From the Department of Physiology and Biophysics and the Center for Excellence in Cardiovascular-Renal Research, University of Mississippi Medical Center, Jackson.
Correspondence to Jane F. Reckelhoff, PhD, Department of Physiology and Biophysics, University of Mississippi Medical Center, 2500 N State St, Jackson, MS 39216-4505. E-mail jreckelhoff{at}physiology.umsmed.edu
 |
Abstract |
|---|
Top
Abstract
IntroductionAbstract—Men are at greater risk for cardiovascular and renal disease than are age-matched, premenopausal women. Recent studies using the technique of 24-hour ambulatory blood pressure monitoring have shown that blood pressure is higher in men than in women at similar ages. After menopause, however, blood pressure increases in women to levels even higher than in men. Hormone replacement therapy in most cases does not significantly reduce blood pressure in postmenopausal women, suggesting that the loss of estrogens may not be the only component involved in the higher blood pressure in women after menopause. In contrast, androgens may decrease only slightly, if at all, in postmenopausal women. In this review the possible mechanisms by which androgens may increase blood pressure are discussed. Findings in animal studies show that there is a blunting of the pressure-natriuresis relationship in male spontaneously hypertensive rats and in ovariectomized female spontaneously hypertensive rats treated chronically with testosterone. The key factor in controlling the pressure-natriuresis relationship is the renin-angiotensin system (RAS). The possibility that androgens increase blood pressure via the RAS is explored, and the possibility that the RAS also promotes oxidative stress leading to production of vasoconstrictor substances and reduction in nitric oxide availability is proposed.
Key Words: sex characteristics • hypertension • angiotensin II • nitric oxide • oxidative stress
|
Introduction |
|---|
In this review gender differences in blood pressure control are explored, including possible mechanisms by which androgens may increase blood pressure.
|
Gender Differences in Blood Pressure Regulation in Humans |
|---|
Men are generally at greater risk for cardiovascular and renal disease than are age-matched, premenopausal women. Recent studies using the technique of 24-hour ambulatory blood pressure monitoring have shown that blood pressure is higher in men than in women at similar ages. As shown in Figure 1, Wiinber and colleagues1 studied 352 normotensive (for age) Danish men and women, aged 20 to 79 years, and found that blood pressure increased with aging in both men and women, but that men had higher 24-hour mean blood pressure, by approximately 6 to 10 mm Hg, than did women, until the age of 70 to 79 years, when blood pressure was similar for men and women. Khoury and colleagues2 performed ambulatory blood pressure monitoring on 131 men and women, aged 50 to 60 years, and found that men had higher blood pressure than did women. Findings were similar in a meta-analysis study performed by Staessen et al.3 In addition, the Third National Health and Nutrition Evaluation Survey (NHANES III) showed that, in general, men had higher blood pressure than women through middle age.4 Furthermore, the incidence of uncontrolled hypertension is also greater in men than in women.5
|
After menopause, however, blood pressure increases in women as well. The data from NHANES III, shown in Figure 2, confirmed that by 60 to 69 years of age, non-Hispanic black and Hispanic women developed higher blood pressure than men of similar ethnic background.4 However, the mechanisms responsible for the hypertension in these populations are complicated by comorbid conditions of obesity and type II diabetes, both of which lead to increases in blood pressure.4 In the non-Hispanic white population, in which the incidence of obesity and type II diabetes with aging is not as high, blood pressure also increased after the average age of menopause (51.4 years). Therefore, by 60 to 69 years of age, non-Hispanic white women had blood pressure similar to that of men, and by 70 to 79 years of age, this population of women had higher blood pressure than did men.4
|
|
Gender Differences in Blood Pressure Regulation in Animals |
|---|
The gender-associated differences in blood pressure observed in humans have also been documented in various animal models. In hypertensive rat models, many investigators have found that males have higher blood pressure than do females. For example, as shown in Figure 3, male spontaneously hypertensive rats (SHR) have higher blood pressure than do females of similar ages.6 7 8 9 Similar gender differences in development of hypertension are also found in Dahl salt-sensitive (DS) rats,10 11 deoxycorticosterone-salt hypertensive rats,12 and the New Zealand genetically hypertensive rat.13 Therefore, as found in humans and hypertensive rat models, males have higher blood pressure than age-matched females.
|
P<0.01 compared with females, castrated males, or ovariectomized females. Data presented with permission from Hypertension.To date there have been no studies in which a consistent gender difference in blood pressure in normotensive animals has been documented. Contrary to data in humans, Calhoun and colleagues14 reported that 24-hour blood pressure measured at 12 weeks of age in male Wistar-Kyoto rats (WKY) was lower than in female WKY by approximately 9 mm Hg (males, 96±3; females, 105±1 mm Hg). However, by 14 weeks of age there was no difference in blood pressure over 24 hours between the genders (males, 101±3; females, 106±1 mm Hg).14 It is possible that averaging blood pressure over 24 hours would diminish gender differences that would be exposed when blood pressure is evaluated during the day or night individually. In any case, from the small differences in blood pressure found in normotensive human subjects, it is clear that blood pressure measurement in conscious rats during acute studies is not sufficient to be able to detect the small differences one would expect to find between normotensive male and female rats. Thus, it will be necessary to measure telemetric blood pressure in normotensive rats over a prolonged (months) period of time to determine whether there are in fact gender differences with increasing age in normotensive rats, as found in normotensive humans.
|
Mechanisms for Gender Differences in Blood Pressure Control: Role of Testosterone |
|---|
Although the mechanisms responsible for the gender differences in blood pressure control are not clear, there is significant evidence that androgens, such as testosterone, play an important role in gender-associated differences in blood pressure regulation. For example, studies using ambulatory blood pressure monitoring techniques in children have shown that with increasing age, blood pressure increases in both boys and girls. However, after the onset of puberty, boys have higher blood pressure than do age-matched girls.15 16 At ages 13 to 15 years, systolic blood pressure was approximately 4 mm Hg higher in boys than girls, and at ages 16 to 18 years, boys had higher systolic blood pressures than girls by 10 to 14 mm Hg.16 The blood pressure in postpubescent boys also does not dip as low at night as in girls.15 16 A reduction in nocturnal dipping is recognized as a hallmark of early dysfunction in blood pressure regulation.15 16 These data clearly show that in adolescence and puberty, when androgen levels are increasing, blood pressure is higher in boys than in girls.
Another line of evidence that testosterone may play an important role in higher blood pressure in males is castration studies in male rats. Castration at a young age (3 to 5 weeks) attenuates the development of hypertension in SHR (Figure 3), in DS male rats, in male rats subjected to 2-kidney, 1 clip (Goldblatt) maneuver,6 7 9 10 11 17 18 and in male rats subjected to reduced renal mass.19 20 Furthermore, as shown in Figure 4, we have found that chronic blockade of the androgen receptor with the antagonist flutamide attenuates blood pressure in male SHR to the level found in female SHR.21 Both testosterone and dihydrotestosterone (DHT) bind to the androgen receptor, and DHT rather than testosterone is the androgen involved in such conditions as male pattern baldness and benign prostatic hypertrophy.22 23 When treated with finasteride, the inhibitor of the conversion of testosterone to DHT, baldness of this type is attenuated, and the prostatic hypertrophy is reversed.22 23 However, conversion to DHT was not found to be important in promoting hypertension in male SHR because chronic treatment with finasteride did not have an effect on the hypertension.21
|
On the other hand, increases in androgens in humans and animals increase blood pressure. Women with polycystic ovary syndrome or adrenal virilizing tumors, which are characterized by elevated testosterone levels, experience hypertension.24 25 26 In animal studies testosterone treatment increases blood pressure in ovariectomized female and castrated male SHR (Figure 3).9 27 Furthermore, chronic testosterone treatment of normotensive, uninephrectomized female rats increases arterial blood pressure that was found not to be reversible, depending on the length of time the testosterone was given.28 29 Thus, increases in androgens in humans and in normotensive and hypertensive rats lead to higher blood pressure.
|
Mechanisms for Gender Differences in Blood Pressure Control: Role of Estrogens |
|---|
Because men and male rats have higher blood pressures than do females, it is possible that female hormones may play a role in protecting females from developing higher blood pressures. In women menopause is characterized by increases in blood pressure, as determined by the NHANES III study and others (Figure 2).4 30 31 Interestingly, the blood pressure does not increase during the transitional phase from perimenopause to menopause,32 but rather the increase in blood pressure after menopause takes an average of 5 to 20 years to develop,4 suggesting that lack of female hormones may not be the only contributing factor for the elevated blood pressure.
|
Hormone Replacement Therapy in Postmenopausal Women |
|---|
The possibility that lack of female hormones may not be the only factor contributing to the increase in blood pressure after menopause is supported by the numerous studies in postmenopausal women given hormone replacement therapy (HRT), in whom blood pressure was measured by ambulatory blood pressure monitoring techniques. In these studies, blood pressure was not affected by HRT,33 34 35 was only minimally affected by HRT,36 37 38 or the reduction in blood pressure with HRT was evident only at night38 or only in normotensive individuals.39 Furthermore, the route of delivery was important in whether HRT was effective in lowering blood pressure, with transdermal HRT being more effective than oral preparations.34 38 Importantly, the Heart and Estrogen/Progestin Replacement Study (HERS) also found that there was no overall beneficial effect on secondary prevention of coronary heart disease in postmenopausal women during the 4.1 years of study.40
Estrogen has been shown to stimulate nitric oxide (NO) production.41 42 Thus, loss of estrogen with menopause could play a role in the increased blood pressure in women after menopause. However, since estrogen replacement therapy has not been shown to decrease blood pressure, it is doubtful that the effect of estrogen on NO is the protective mechanism by which blood pressure is lower in premenopausal women. We have shown in previous studies that aging in rats is associated with a reduction in NO substrate (L-arginine) and excretion of NO metabolites.43 Thus, it is also possible that the effect of advanced age on other components of the NO overwhelms the effect of estrogen on NO production in postmenopausal women.
|
Androgens in Postmenopausal Women |
|---|
With regard to androgen levels after menopause, there is some controversy since studies have shown that serum testosterone levels in postmenopausal women may decrease slightly, may not change at all, or may actually increase.44 45 46 47 A recent report from the Rancho Bernardo Study, a community-living, population-based study in Rancho Bernardo, Calif, emphasized that in 685 women, aged 50 to 89 years, the status of whether or not the women had undergone hysterectomy with or without oophorectomy affected serum testosterone levels.48 These investigators found that in intact women serum testosterone levels decreased immediately after menopause but increased with aging to premenopausal levels by 70 to 79 years of age.48 In women who had undergone hysterectomy with bilateral oophorectomy, both total and bioavailable testosterone levels were reduced by 40%. Postmenopausal women who had undergone hysterectomy without oophorectomy had intermediate serum testosterone levels.48 These data show that the ovary is a very important source of androgens after menopause in women. Since increased androgen levels have been shown to increase BP in women with polycystic ovary syndrome and in animal models, it is possible that with the loss of estrogens at menopause, the unopposed effect of androgens in postmenopausal women may contribute to their elevated BP. This hypothesis remains to be tested in both women and female animal models.
|
Role of Female Hormones in Blood Pressure Control in Animal Models |
|---|
Studies in female SHR have supported the notion that female hormones do not cause protection against the higher blood pressure found in male SHR. As shown in Figure 3, ovariectomy of female SHR at 4 to 5 weeks of age does not result in higher blood pressures than in intact females at 18 to 20 weeks of age.27 49 However, androgen treatment of ovariectomized female SHR causes an increase in blood pressure that is dose dependent.27 49 These data suggest that it is not female hormones but rather lack of testosterone that may protect female SHR from the higher blood pressure found in males.
There are differences in rat models of hypertension with regard to the role that ovariectomy plays in the control of blood pressure in female rats. Hinojosa-Laborde and colleagues50 found that ovariectomy of DS rats resulted in higher blood pressure than in either males or females. When rats were maintained on a high salt diet, blood pressure increased in all rats, but to a greater extent in males and ovariectomized females than in intact females. Surprisingly, reversal of the diet to low salt in these animals reversed the hypertension in intact male and female DS rats but not in ovariectomized DS rats.50 Similar effects of ovariectomy in causing an increase in blood pressure compared with intact females have also been found in females in the model of deoxycorticosterone-salt hypertension.51 It is not clear why loss of female sex hormones results in elevation of blood pressure in these models.
|
Abnormal Pressure-Natriuresis in Hypertension: Role Played by Testosterone |
|---|
Substantial evidence supports the theory that some form of renal dysfunction plays a role in the development and maintenance of hypertension.52 53 Providing the strongest support for this theory are observations that transplantation of prehypertensive kidneys from SHR to WKY produces hypertension.53 Similar results have been obtained in renal transplantation studies between DS and Dahl salt-resistant rats.53 Of particular relevance to human hypertension is the study by Curtis et al,54 which demonstrated that blood pressure returns to normal in hypertensive patients who receive kidneys from normotensive donors. The results indicate that a defect within the kidney may play a crucial role in the pathogenesis of hypertension. A common defect that has been characterized in several forms of hypertension is a shift in the pressure-natriuresis relationship.53 The pressure-natriuresis relationship refers to the fact that increased arterial pressure elicits a marked increase in sodium excretion.55 56 According to the renal body fluid feedback concept, a long-term increase in arterial pressure or hypertension occurs as a result of reduction in renal excretory function or a rightward shift in the pressure-natriuresis relationship.55 56
As shown in Figure 5, we have recently reported that the pressure-natriuresis relationship is blunted in male SHR compared with females.27 Castration of the male SHR restored the pressure-natriuresis relationship, whereas ovariectomy of female SHR had no effect.27 Testosterone treatment of ovariectomized female SHR resulted in an increase in blood pressure and a concomitant blunting of the pressure-natriuresis relationship.27 Preliminary data have shown that the androgen receptor is located predominantly in proximal tubule segments of the nephron.57 These data provide initial support for the notion that androgens may have a direct effect on sodium reabsorption in the proximal nephron.
|
As mentioned above, many studies have demonstrated that "hypertension follows the kidney"; accordingly, when the kidney of SHR is transplanted into a normotensive rat, the blood pressure in the previously normotensive rat increases.53 However, Harrap and colleagues58 reported that when the kidney from male SHR was transplanted into female SHR, this maneuver did not result in a significant rise in blood pressure such that female SHR with male kidneys had blood pressure similar to that in female SHR with female kidneys. However, when the kidney from female SHR was transplanted into male SHR, blood pressure was not attenuated in the male with female kidneys compared with blood pressure in a male SHR with male kidneys.58 These data indicate that the 25 to 30 mm Hg higher blood pressure in the male SHR compared with the female is not due to an intrinsic defect of the male kidney but rather is due to some external factor in the male that further increases blood pressure, perhaps because of a reduction in pressure-natriuresis. We hypothesize that androgens are the factor in males by which the pressure-natriuresis relationship is blunted and higher blood pressure results.
|
Testosterone-Induced Reduction in Pressure-Natriuresis: Role of the Renin-Angiotensin System |
|---|
The key system for controlling blood pressure and body fluid volume (ie, pressure-natriuresis) is the renin-angiotensin system (RAS).55 56 For example, under normal conditions, any perturbation that increases arterial pressure will also provoke an increase in sodium and water excretion via pressure-natriuresis. This will lead to a decrease in extracellular fluid volume, venous return, and cardiac output, and blood pressure will return to normal. Long-term pressure-natriuresis is modulated by the RAS. Angiotensin II (Ang II) increases proximal sodium reabsorption by the kidney by stimulating epithelial transport.56 In the event of abnormal Ang II levels for the level of volume in the body, the blood pressure will increase with abnormal sodium and water reabsorption, leading to blunting of the pressure-natriuresis relationship. Similarly, if total body fluid volume levels are "perceived" incorrectly, and thus Ang II levels do not respond appropriately, increases in blood pressure will also occur.59
Gender differences in components of the RAS have been shown to exist that may play a role in the control of blood pressure. James and colleagues60 measured plasma renin activity (PRA) in men and women over a 9-year period and documented that in this normotensive population, PRA was 27% higher in men than in women regardless of age and ethnic heritage. Kaplan and associates61 reported similar findings. Other studies in older individuals have shown that PRA is higher in postmenopausal women than in premenopausal women but that PRA is still higher in men than in women of similar age.62 Thus, renin activity is greater in men than in women. The cause of this gender difference is unclear. However, these data lend credence to the hypothesis that the RAS may play a role in mediating the gender difference in blood pressure regulation.
In animal studies, male SHR have higher PRA than do females,63 testosterone treatment of ovariectomized female rats causes increases in PRA,64 65 and PRA decreases with castration in male rats.64 65 Furthermore, as presented in Figure 6, we have found that there is a linear correlation (r=0.904) between the level of serum testosterone and PRA in Sprague-Dawley rats treated chronically (2 weeks) with increasing doses of testosterone. Blood pressure also increases with chronic testosterone in normotensive rats. Therefore, these data suggest that testosterone stimulates the RAS. The mechanism by which androgens increase PRA is not clear, but data from 2 groups have independently shown in SHR and normotensive WKY that castration decreases renal angiotensinogen mRNA and chronic testosterone increases renal angiotensinogen mRNA.64 66 Chronically increased renal angiotensinogen could increase renal tissue Ang II if renin enzyme is not working at maximal velocity, which has been reported in both humans and rats.67 In support of this hypothesis, studies in mice have demonstrated that an increase in angiotensinogen gene copy numbers causes increases in blood pressure.68 Alternatively, if testosterone plays a role in directly increasing proximal sodium reabsorption, as hypothesized above, the reduction in tubular sodium would be perceived by the macula densa and would therefore result in renin release, causing an increase in PRA. Future studies will be necessary to determine the exact mechanism by which androgens increase PRA.
|
To test the hypothesis that the RAS plays a role in mediating the gender difference in blood pressure in SHR, we found that chronic blockade with the Ang II–converting enzyme inhibitor enalapril resulted in normalization of the blood pressure regardless of gender,49 thus removing the gender-induced difference in blood pressure in SHR (Figure 7). In male SHR and ovariectomized female SHR treated with testosterone, in which blood pressure was elevated by 30 mm Hg, blood pressure was reduced by 65% with enalapril, whereas in female, castrated male, and untreated ovariectomized female SHR, blood pressure was only reduced by 40%.49 These data suggest that the RAS plays an important role in mediating the hypertension in SHR regardless of gender, but, more importantly, that the androgen-promoted exacerbation of the blood pressure in male and testosterone-treated ovariectomized female SHR is also mediated by the RAS.
|
|
Mechanism(s) by Which Ang II May Increase Blood Pressure in Males: Role of Oxidative Stress |
|---|
Both supraphysiological and physiological doses of Ang II can cause oxidative stress. For example, Rajagopalan and colleagues69 found that pharmacological doses of Ang II (0.7 mg/kg per day SC by minipump) increased blood pressure and superoxide levels in aortic segments of rats, while infusion of norepinephrine, which resulted in an increase in blood pressure similar to that of Ang II, had no effect on superoxide levels. These data suggested that infusion of Ang II at pharmacological doses was capable of inducing oxidative stress independent of elevated blood pressure. In addition, these investigators found that increased superoxide levels could be normalized with losartan, the Ang II receptor antagonist, or with liposomes containing superoxide dismutase.69 In additional experiments they also reported that Ang II increases superoxide production via increased NAD(P)H oxidase activity.70
Superoxide is known to interact with NO to produce peroxynitrite, one of the most potent oxidative compounds known.71 72 Thermodynamically speaking, the reaction of NO and superoxide is preferential since the rate of reaction is more rapid than the reaction rate of superoxide and its scavenger, superoxide dismutase.73 Although peroxynitrite itself is a vasodilator, Villa and colleagues74 demonstrated that tachyphylaxis occurs at peroxynitrite concentrations of 3 µmol/L, which is subthreshold as a vasodilator in coronary circulation; this not only prevents further response to its own vasodilator actions but also causes long-lasting impairment of the response to other vasodilators. In support of this notion, Benkusky and colleagues75 found that the development of tachyphylaxis to peroxynitrite attenuated the hemodynamic vasodilator effect produced by systemic administration of acetylcholine and prostacyclin in hindquarter, renal, and mesenteric circulation. Furthermore, Kooy and Lewis76 reported that after tachyphylaxis to peroxynitrite infusion, blood pressure in rats increased by 20% and renal vascular resistance increased by 93%, along with increases in hindquarter and mesenteric vascular resistances. Therefore, the vasodilator action of peroxynitrite will play only a minimal role in control of vascular tone, if at all. However, not only will quenching of NO by superoxide increase the vascular tone, but the increase in peroxynitrite could potentiate this effect by causing tachyphylaxis to residual NO.
It may not be surprising that high doses of Ang II could
cause oxidative stress since Ang II is a powerful vasoconstrictor;
however, we have recently shown that chronic infusion of subpressor
doses (ie, doses that do not elicit an immediate blood pressure
response) of Ang II (10 ng/kg per minute) for 14 days to normotensive
rats that were given enalapril to block endogenous Ang II
formation resulted in the slow-onset development of hypertension and an
increase in plasma F2-isoprostanes, an indicator
of oxidative stress.77 Two
factors suggest that the increase in blood pressure in this model may
require a secondary mechanism in addition to Ang II itself. The first
is the time delay required for the increase in blood pressure to
develop (5 to 10 hours, typically reaching a maximum in 4 to 5
days),77 78 and
the second is lack of a significant increase in plasma Ang II
levels accompanying the increase in blood
pressure.59 79
Peroxynitrite, by virtue of its potent oxidative ability, can produce
oxidation of lipids and produce other products that have
vasoconstrictive actions. One such group of compounds
are the isoprostanes, which are prostaglandin-like
compounds produced by nonenzymatic, free radical–induced peroxidation
of arachidonic
acid.80 One of the F-ring
isoprostanes (8-iso-prostaglandin
F2
or F2-isoprostanes)
has been shown to be a very potent renal vasoconstrictor, mainly by
increasing afferent resistance, and can also raise blood pressure at
higher
doses.80 81 In
addition, Sametz and
colleagues82 recently
reported that coinfusion of F2-isoprostane and
Ang II resulted in significant potentiation of the vasoconstrictor
effect of Ang II. Furthermore, F2-isoprostanes
have been shown to increase
endothelin,83 which would
also contribute to renal vasoconstriction. We hypothesize that
androgens stimulate the RAS and increase Ang II, which causes oxidative
stress with increased superoxide production, quenching of NO
(leading to a further increase in blood pressure), and
production of peroxynitrite, which causes a reduction in the
renal vascular response to vasodilators, including residual NO, and
production of vasoconstrictor
F2-isoprostanes, which will in turn potentiate
the vasoconstrictor effects of Ang II and stimulate endothelin
production to increase blood pressure even further. To extend
this hypothesis, thromboxane receptor number has been shown
to increase with testosterone treatment in aortic vascular smooth
muscle cells.84
Thromboxane receptors have been shown to mediate at least in
part the biological action of
F2-isoprostanes.85
Thus, androgens could also increase the number of
thromboxane receptors by which the
F2-isoprostanes cause vasoconstriction. It is
doubtful that thromboxanes themselves play any role in
mediating the higher blood pressure in male SHR since, as shown in
Figure 8, we have found that male SHR excrete less
thromboxane B2, the stable
metabolite of thromboxane A2, than
do females.
|
In support of the hypothesis that oxidative stress, and more directly superoxide, plays a role in the hypertension in male SHR, we have preliminary data in which SHR were chronically treated with the chemical scavenger of superoxide, TEMPOL, for 6 weeks.63 With TEMPOL treatment, the mean arterial pressure of SHR males was attenuated to the level found in untreated female SHR. Chronic TEMPOL also decreased PRA in male SHR to levels found in untreated female SHR. In contrast, there was no effect of TEMPOL on blood pressure or PRA in female SHR.63 Together with the data from our enalapril studies in SHR discussed above, these preliminary data provide strong evidence that Ang II and oxidative stress play important roles in the higher blood pressure in male SHR.
Figure 9 serves to illustrate the possible mechanisms by which oxidative stress could play a role in at least partially mediating androgen-induced increases in blood pressure. Androgens could stimulate superoxide production either directly or via the effect of Ang II on NAD(P)H oxidases. Superoxide production would quench NO, leading to vasoconstriction. The combination of superoxide and NO produces peroxynitrite, which would oxidize arachidonic acid to produce F2-isoprostanes. F2-isoprostanes, mediated by thromboxane receptors, which are upregulated by androgens, would cause renal vasoconstriction directly and indirectly by potentiating the vasoconstrictor actions of Ang II and stimulating endothelin production, which in turn would cause further renal vasoconstriction. These hypotheses remain to be tested.
|
|
Other Mechanism(s) by Which Androgens May Influence Blood Pressure: Role of Ang II Receptors |
|---|
One mechanism by which androgens may affect the sensitivity to Ang II is by exerting an effect on Ang II receptors in the kidney. In contrast to female SHR and female rats subjected to reduced renal mass, female DS rats on a high salt diet exhibit an increase in blood pressure after ovariectomy.86 87 Nickenig and colleagues88 reported that ovariectomy of normotensive rats results in an increase in angiotensin type 1 (AT1) receptor number in the aorta. In preliminary studies by Harrison-Bernard and Raij,86 AT1 receptor concentration in the kidney was found to be higher in ovariectomized female DS rats. It is possible that the increase in blood pressure in DS rats after ovariectomy may result from the increase in renal AT1 receptor number. Angiotensin type 2 (AT2) receptors are thought to be associated with the vasodilatory actions of Ang II, which may be mediated by NO,89 and it is possible that male SHR also have lower AT2 receptor numbers than females, which could contribute to the higher blood pressure in males than in females. To date there have been no studies to determine whether androgens affect the Ang II receptor subtypes, numbers, or affinity.
|
Other Mechanism(s) by Which Androgens May Influence Blood Pressure: Role of Aldosterone |
|---|
Ang II stimulates the production of aldosterone, which is responsible for increasing sodium reabsorption in the distal nephron. It is possible that androgens could increase sodium reabsorption via Ang II–mediated or androgen-mediated increases in aldosterone. There is evidence to suggest that this may be the case, since Miller and colleagues90 found higher blood pressure and aldosterone levels in men than in women, and Schunkert et al91 found a positive correlation between dehydroepiandrosterone sulfate (a metabolite of testosterone), aldosterone levels, and blood pressure in a population of hypertensive men. However, Kau and colleagues92 reported that testosterone replacement in castrated male rats decreased corticotropin-stimulated aldosterone release.
|
Mechanistic Scheme |
|---|
This review has attempted to critically examine large numbers of fragmentary observations to create a coherent set of hypotheses (albeit complicated) by which gender differences in blood pressure control may be explained. The speculative hypotheses described in Figure 9 represent the possible mechanisms by which androgens, mediated via Ang II, could induce oxidative stress to potentiate renal vasoconstriction. In Figure 10 are illustrated the mechanisms by which androgen-mediated increases in Ang II could lead to a shift in the pressure-natriuresis relationship and renal vasoconstriction, both of which are known to affect blood pressure. As we have shown in animal studies, androgens could promote an increase in blood pressure in males by stimulating renin activity and Ang II formation, either by stimulating renin release and/or by increasing renal renin activity. Androgens may stimulate renin release by reducing glomerular filtration rate, directly stimulating sodium reabsorption, and thus decreasing delivery of sodium to the macula densa. Alternatively, renin activity (and thus Ang II) could also be increased if androgens cause a chronic increase in renal angiotensinogen and renin enzyme is working below its maximal velocity. Androgens may affect the number and affinity of receptors for Ang II, thereby affecting sodium reabsorption and/or renal vasoconstriction. Ang II via AT1 receptors may directly cause renal vasoconstriction and may also stimulate proximal tubule sodium reabsorption and/or stimulate aldosterone-mediated distal tubule sodium reabsorption, blunt pressure-natriuresis, and increase blood pressure. The combination of increased sodium reabsorption and renal vasoconstriction would lead to the increase in blood pressure.
|
If androgen levels are similar in normotensive and hypertensive rats and yet blood pressure differences are difficult to detect in normotensive rats but are very obvious in hypertensive rat strains, this may suggest that hypertensive rats may exhibit an exaggerated response to androgens that normotensive rats do not. This is intriguing because increasing responsiveness to androgens may be an important factor in why postmenopausal women experience increases in blood pressure, if in fact androgen levels are not significantly reduced with aging in women44 45 46 47 and are left unopposed because of lack of estrogen. The increasing response to androgens could be mediated by changes in Ang II receptors, aldosterone, and/or oxidative stress. Future studies will be necessary to investigate these possibilities.
|
Acknowledgments |
|---|
This work was supported by National Institutes of Health grant HL-51971 and by an Established Investigator Award from the American Heart Association. We also thank Dr Manis Smith, University of Mississippi Medical Center, Jackson, for measurement of urinary thromboxane B2. The author would also like to thank Dr J.C. Romero, Mayo Clinic and Foundation, Rochester, Minn, for helpful suggestions and commentary during the preparation of the manuscript.
Received August 21, 2000; first decision October 24, 2000; accepted October 24, 2000.
|
References |
|---|
1. Wiinber N, Hoegholm A, Christensen HR, Bang LE, Mikkelsen KL, Nielsen PE, Svendsen TL, Kampmann JP, Madsen NH, Bentzon MW. 24-h Ambulatory blood pressure in 352 normal Danish subjects, related to age and gender. Am J Hypertens. 1995;8:978–986.[Medline] [Order article via Infotrieve]
2. Khoury S, Yarows SA, O’Brien TK, Sowers JR. Ambulatory blood pressure monitoring in a nonacademic setting: effects of age and sex. Am J Hypertens. 1992;5:616–623.[Medline] [Order article via Infotrieve]
3. Staessen J, Fagard R, Lijnen P, Thijs L, Van Hoof R, Amery A. Reference values for ambulatory blood pressure: a meta-analysis. J Hypertens. 1990;8(suppl 6):S57–S64.
4. Burl VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension. 1995:25: 305–313.
5. Anastos K, Charney P, Cohen E, Jones CY, Marte C, Swiderski DM, Wheat ME, Williams S. Hypertension in women: what is really known? The Women’s Caucus, Working Group on Women’s Health of the Society of General Internal Medicine. Ann Intern Med. 1991;115:287–293.
6. Ganten U, Schroder G, Witt M, Zimmerman F, Ganten D, Stock G. Sexual dimorphism of blood pressure in spontaneously hypertensive rats: effects of anti-androgen treatment. J Hypertens. 1989;7:721–726.[Medline] [Order article via Infotrieve]
7.
Masubuchi Y, Kumai
T, Uematsu A, Komoriyama K, Hirai M.
Gonadectomy-induced reduction in blood pressure in
adult spontaneously hypertensive rats.
Acta Endocrinol (Copenh). 1982;101:154–160.
8.
Iams SG, McMurtry
JP, Wexler BC. Aldosterone, deoxycorticosterone, and
prolactin changes during lifespan of chronically and spontaneously
hypertensive rats.
Endocrinology. 1979;104:1357–1363.
9. Chen Y-F, Meng Q-M. Sexual dimorphism of blood pressure in spontaneously hypertensive rats is androgen dependent. Life Sci. 1991;48:85–96.[Medline] [Order article via Infotrieve]
10. Crofton JT, Ota M, Share L. Role of vasopressin, the renin-angiotensin system, and sex in Dahl salt-sensitive hypertension. J Hypertens. 1993;11:1031–1038.[Medline] [Order article via Infotrieve]
11. Rowland NE, Fregly MJ. Role of gonadal hormones in hypertension in the Dahl salt-sensitive rat. Clin Exp Hypertens. 1992;A14:367–375.
12.
Ouchi Y, Share L,
Crofton JT, Iitake K, Brooks DP. Sex difference in the development of
deoxycorticosterone-salt hypertension in the rat.
Hypertension. 1987;9:172–177.
13.
Ashton N, Balment
RJ. Sexual dimorphism in renal function and hormonal status of New
Zealand genetically hypertensive rats.
Acta Endocrinol (Copenh). 1991;124:91–97.
14.
Calhoun DA, Zhu
S-T, Chen Y-F, Oparil S. Gender and dietary NaCl in spontaneously
hypertensive and Wistar-Kyoto rats.
Hypertension. 1995;26:285–289.
15. Bachmann H, Horacek U, Leowsky M, Hirche H. Blood pressure in children and adolescents aged 4 to 18: correlation of blood pressure values with age, sex, body height, body weight, and skinfold thickness. Monatsschrift Kinderheilkunde. 1987;135:128–134.
16.
Harshfield GA,
Alpert BS, Pulliam DA, Somes GW, Wilson DK. Ambulatory blood pressure
recordings in children and adolescents.
Pediatrics. 1994;94:180–184.
17. Iams SG, Wexler BC. Retardation in the development of spontaneous hypertension in SH rats by gonadectomy. J Lab Clin Med. 1977;90:997–1003.[Medline] [Order article via Infotrieve]
18. Malyusz M, Ehrens H-J, Wrigge P. Effect of castration on the experimental renal hypertension of the rat. Nephron. 1985;40:96–99.[Medline] [Order article via Infotrieve]
19. Lombet JR, Adler SG, Anderson PS, Nast CC, Olsen DR, Glasscock RJ. Sex vulnerability in the subtotal nephrectomy model of glomerulosclerosis in the rat. J Lab Clin Med. 1989;114:66–74.[Medline] [Order article via Infotrieve]
20. Gafter U, Ben-Bassat M, Levi J. Castration inhibits glomerular hypertrophy and proteinuria in uninephrectomized male rats. Eur J Clin Invest. 1990;20:360–365.[Medline] [Order article via Infotrieve]
21.
Reckelhoff JF,
Zhang H, Srivastava K, Granger JP. Gender differences in hypertension
in spontaneously hypertensive rats: role of androgens and androgen
receptor. Hypertension. 1999;34:920–923.
22. Kaufman KD, Olsen EA, Whiting EA, Savin R, DeVillex R, Bergfeld W, Price VH, Van Neste D, Roberts JL, Hardinsky M, Shapiro J, Binkowitz B, Gormley GJ, for the Finasteride Male Pattern Hair Loss Study Group. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39:578–589.[Medline] [Order article via Infotrieve]
23. Marks LS, Partin AW, Dorey FJ, Gormley GJ, Epstein JI, Garris JB, Macairan ML, Shery ED, Santos PB, Stoner E, de Kernion JB. Long-term effects of finasteride on prostate tissue composition. Urology. 1999;53:574–580.[Medline] [Order article via Infotrieve]
24. Soranno D, Prasad V, Oberfield DR, Greco A, Sivaraman N, Drucker W. Hypertension and virilization caused by a unique dexoxycorticosterone and androgen-secreting adrenal adenoma. J Pediatr Endocrinol Metab. 1999;12:215–220.[Medline] [Order article via Infotrieve]
25.
Talbott E, Guzick
D, Clerici A, Berga S, Detre K, Weimer K, Kuller L. Coronary
heart disease risk factors in women with polycystic ovary syndrome.
Arterioscler Thromb Vasc Biol. 1995;15:821–826.
26. Mattson LACG, Hamberger L, Samsioe G, Silfverstolpe G. Lipid metabolism in women with polycystic ovary syndrome: possible implications for an increased risk of coronary heart disease. Fertil Steril. 1984;42:579–584.[Medline] [Order article via Infotrieve]
27.
Reckelhoff JF,
Zhang H, Granger JP. Testosterone exacerbates hypertension and reduces
pressure-natriuresis in male spontaneously hypertensive rats.
Hypertension. 1998;31:435–439.
28. Oudar O, Elger M, Bankir L, Ganten D, Ganten U, Kriz W. Differences in rat kidney morphology between males, females, and testosterone-treated females. Ren Physiol Biochem.. 1991;14:92–102.[Medline] [Order article via Infotrieve]
29.
Colby HD, Skelton
FR, Brownie AC. Testosterone-induced hypertension in the rat.
Endocrinology. 1970;86:1093–1101.
30.
August P, Oparil
S. Commentary: hypertension in women.
J Clin Endocrinol Metab. 1999;84:1862–1866.
31. Calhoun DA, Oparil S. The sexual dimorphism of high blood pressure. Cardiol Rev. 1998;6:356–363.[Medline] [Order article via Infotrieve]
32. Luoto R, Sharrett AR, Schreiner P, Sorlie PD, Arnett D, Ephross S. Blood pressure and menopause transition: the Atherosclerosis Risk in Communities Study (1987–1995). J Hypertens. 2000;18:27–33.[Medline] [Order article via Infotrieve]
33.
The Writing Group
for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens
on heart disease risk factors in postmenopausal women: the
Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.
JAMA. 1995;273:199–208.
34. Akkad AA, Halligan AW, Abrams K, al-Azzawi F. Differing responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal estrogen replacement therapy. Obstet Gynecol. 1997;89:97–103.[Medline] [Order article via Infotrieve]
35. Pripp U, Hall G, Csemiczky G, Eksborg S, Landgren BM, Schenck-Gustafsson K. A randomized trial on effects of hormone therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease. J Hypertens. 1999;17:1379–1386.[Medline] [Order article via Infotrieve]
36. Manhem K, Ahlm H, Milsom I, Svensson A. Transdermal oestrogen reduces daytime blood pressure in hypertensive women. J Hum Hypertens. 1998;12:323–327.[Medline] [Order article via Infotrieve]
37. van Ittersum FJ, Van Baal WM, Kenemans P, Mijatovic V, Donker AJ, van der Mooren MJ, Stehouwer CD. Ambulatory—not office—blood pressures decline during hormone replacement therapy in healthy postmenopausal women. Am J Hypertens. 1998;11:1147–1152.[Medline] [Order article via Infotrieve]
38.
Seely EW, Walsh
BW, Gerhard MD, Williams GH. Estradiol with or without progesterone and
ambulatory blood pressure in postmenopausal women.
Hypertension. 1999;33:1190–1194.
39. Beljic T, Babic D, Marinknvic J, Prelevic GM. The effect of hormone replacement therapy on diastolic left ventricular function in hypertensive and normotensive postmenopausal women. Maturitas. 1998;29:229–238.[Medline] [Order article via Infotrieve]
40.
Herrington DM.
The HERS trial results: paradigms lost? Heart and Estrogen/Progestin
Replacement Study. Ann Intern
Med. 1999;131:463–466.
41.
Weiner CP,
Lizasain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of
calcium dependent NO synthase by sex hormones.
Proc Natl Acad Sci
U S A. 1994;91:5212–5216.
42. Goetz RM, Morano I, Calovini T, Studer R, Holtz J. Increased expression of endothelial constitutive NO synthase in rat aorta during pregnancy. Biochem Biophys Res Commun. 1994;205:905–910.[Medline] [Order article via Infotrieve]
43. Reckelhoff JF, Kellum JA, Blanchard EJ, Bacon EE, Wesley AJ, Kruckeberg WC. Changes in nitric oxide precursor, L-arginine, and metabolites, nitrate and nitrite, with aging. Life Sci. 1994;55:1895–1902.[Medline] [Order article via Infotrieve]
44. Hartmann BW, Kirchengast S, Albrecht A, Laml T, Soregi G, Huber JC. Androgen serum levels in women with premature ovarian failure compared to fertile and menopausal controls. Gynecol Obstet Invest. 1997;44:127–131.[Medline] [Order article via Infotrieve]
45. Overlie I, Moen MH, Morkrid L, Skjaeraasen JS, Holte A. The endocrine transition around menopause: a five year prospective study with profiles of gonadotropins, estrogens, androgens and SHBG among healthy women. Acta Obstet Gynecol Scand. 1999;78:642–647.[Medline] [Order article via Infotrieve]
46. Ala-Fossi SL, Maenpaa J, Aine R, Punnonen R. Ovarian testosterone secretion during perimenopause. Maturitas. 1998;29:239–245.[Medline] [Order article via Infotrieve]
47. Jiroutek MR, Chen MH, Johnston CC, Longcope C. Changes in reproductive hormones and sex hormone-binding globulin in a group of postmenopausal women measured over 10 years. Menopause. 1998;5:90-94.[Medline] [Order article via Infotrieve]
48.
Laughlin GA,
Barrett-Connor E, Kritz-Silverstein D, von Muhlen D. Hysterectomy,
oophorectomy, and endogenous sex hormone levels in older
women: the Rancho Bernardo Study. J
Endocrinol Metab. 2000;85:645–651.
49.
Reckelhoff JF,
Zhang H, Srivastava K. Gender differences in the development of
hypertension in SHR: role of the renin-angiotensin system.
Hypertension. 2000;35:480–483.
50.
Hinojosa-Laborde
C, Lange DL, Haywood JR. Role of female sex hormones in the development
and reversal of Dahl hypertension.
Hypertension. 2000;35:484–489.
51.
Crofton JT, Share
L. Gonadal hormones modulate deoxycorticosterone-salt hypertension in
male and female rats.
Hypertension. 1997;29:494–499.
52. Guyton AC, Coleman TG, Cowley AW Jr, Scheel KW, Manning RD, Norman RA. Arterial pressure regulation: overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med. 1972;52:584–594.[Medline] [Order article via Infotrieve]
53.
Hall JE, Mizelle
HL, Hildebrandt DA, Brands MW. Abnormal pressure-natriuresis: a cause
or a consequence of hypertension.
Hypertension. 1990;15:547–559.
54. Curtis JJ, Luke HP, Dustan HP, Kashgarian M, Whelchel JD, Jones P, Diethelm A. Remission of hypertension after renal transplantation. N Engl J Med. 1983;309:1009–1015.[Abstract]
55. Hall JE, Guyton AC, Brands MJ. Control of sodium excretion and arterial pressure by intrarenal mechanisms and the renin-angiotensin system. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York, NY: Raven Press; 1995:1451–1475.
56. Hall JE, Brands MJ, Henegar JR. Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. J Am Soc Nephrol. 1999;10:S258–S265.
57. Hennington BS, Henegar L, Sinning AR, Granger JP, Reckelhoff JF. Localization of androgen receptors in the kidney of male rats. Hypertension. 1997;30:510. Abstract.
58.
Harrap SB, Wang
BZ, MacClellan DG. Renal transplantation between male and female
spontaneously hypertensive rats.
Hypertension. 1992;19:431–434.
59.
Romero JC,
Reckelhoff JF. Role of angiotensin and oxidative stress in
essential hypertension.
Hypertension. 1999;34:943–949.
60. James GD, Sealey JE, Muller F, Alderman M, Madhavan S, Laragh JH. Renin relationship to sex, race and age in normotensive population. J Hypertens. 1986;4(suppl 5):S387–S389.
61. Kaplan NM, Kem DC, Holland OB. The intravenous furosemide test: a simple way to evaluate renin responsiveness. Ann Intern Med. 1976;4:639–645.
62.
Schunkert H,
Danser AHJ, Hense H-W, Derkx FHM, Kurzinger S, Riegger GAJ. Effects of
estrogen replacement therapy on the renin-angiotensin
system in post-menopausal women.
Circulation. 1997;95:39–45.
63. Reckelhoff JF, Fortepiani LA, Zhang H, Srivastava K, Smith MJ. Gender differences in the response of SHR to acute and chronic superoxide dismutase mimetic, TEMPOL. Am J Hypertens. 2000;13:277A. Abstract.
64. Ellison KE, Ingelfinger JR, Pivor M, Dzau VJ. Androgen regulation of rat renal angiotensinogen messenger RNA expression. J Clin Invest. 1989;83:1941–1945.
65. Katz FH, Roper EF. Testosterone effect on renin system in rats. Proc Soc Exp Biol Med. 1977;155:330–333.[Medline] [Order article via Infotrieve]
66.
Chen Y-F,
Naftilan AJ, Oparil S. androgen-dependent angiotensinogen
and renin messenger RNA expression in hypertensive rats.
Hypertension. 1992;19:456–463.
67. Johnston CI, Fabris B, Jandeleit K. Intrarenal renin-angiotensin system in renal physiology and pathophysiology. Kidney Int. 1993;44(suppl 42):S-59–S-63.
68.
Smithies O. A
mouse view of hypertension.
Hypertension. 1997;30:1318–1324.
69. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrision DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916–1923.[Medline] [Order article via Infotrieve]
70.
Usio-Fukai M,
Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox is a critical
component of the superoxide-generating NADH/NADPH oxidase system and
regulates angiotensin II-induced hypertrophy in
vascular smooth muscle cells. J Biol
Chem. 1996;271:23317–23321.
71.
Pryor WA,
Squadrito GL. The chemistry of peroxynitrite: a product from the
reaction of nitric oxide with superoxide.
Am J Physiol. 1995;268:L699–L722.
72. van der Vliet A, Eiserich JP, O’Neill CA, Halliwell B, Cross CE. Tyrosine modification by reactive nitrogen species: a closer look. Arch Biochem Biophys. 1995;319:341–349.[Medline] [Order article via Infotrieve]
73. Ischiropoulos H, Al-Mehdi AB. Peroxynitrite-mediated oxidative protein modifications. FEBS Lett. 1995;364:279–282.[Medline] [Order article via Infotrieve]
74.
Villa LM,
Darley-Usmar VM, Radomski MW, Moncada S. Peroxynitrite induces both
vasodilatation and impaired vascular relaxation in the isolated rat
heart. Proc Natl Acad Sci
U S A. 1994;91:12383–12387.
75. Benkusky NA, Lewis SJ, Kooy NW. Attenuation of vascular relaxation after development of tachyphylaxis to peroxynitrite in vivo. Am J Physiol. 1998;275:H501–H507.
76. Kooy NW, Lewis SJ. Elevation in arterial blood pressure following the development of tachyphylaxis to peroxynitrite. Eur J Pharmacol. 1996;307:R5–R7.[Medline] [Order article via Infotrieve]
77.
Reckelhoff JF,
Zhang H, Srivastava K, Roberts LJ Jr, Morrow JD. Subpressor doses of
angiotensin II increase plasma
F2-isoprostanes in rats.
Hypertension. 2000;35:476–479.
78. Lever AF. The fast and slowly developing pressor effect of angiotensin II. In: Ian J, Robertson S, Nicholls MG, eds. The Renin-Angiotensin System. London, England: Gower Medical Publishing; 1993:28.1–28.9.
79.
Brown AJ,
Casals-Stenzel J, Gofford S, Lever AJ, Morton JJ. Comparison of
fast and slow pressor effects of angiotensin II in the rat.
Am J Physiol. 1981;241:H381–H388.
80.
Morrow JD, Hill
KE, Burk RF, Nammour RM, Badr KF, Roberts ILJ. A series of
prostaglandin F2-like compounds are produced in vivo in
humans by a noncyclooxygenase, free
radical-catalyzed mechanism. Proc Natl
Acad Sci
U S A. 1990;87:9383–9387.
81. Takahashi K, Nammour TM, Fukunaga M, Ebert J, Morrow JD, Roberts ILJ, Hoover RL, Badr KF. Glomerular action of a free radical generated novel prostaglandin, 8-epi-prostaglandin F2-alpha, in the rat. J Clin Invest. 1992;90:136–141.
82. Sametz W, Grobuschek T, Hammer-Kogler S, Juan H, Wintersteiger R. Influence of isoprostanes on vasoconstrictor effects of noradrenaline and angiotensin II. Eur J Pharmacol. 1999;378:47–55.[Medline] [Order article via Infotrieve]
83. Yura T, Fukunaga M, Kahn R, Nassar GN, Badr K, Montero A. Free-radical-generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells. Kidney Int. 1999;56:471–478.[Medline] [Order article via Infotrieve]
84.
Masuda A, Mathur
R, Halushka PV. Testosterone increases thromboxane A2
receptors in cultured rat aortic smooth muscle cells.
Circ Res. 1991;69:638–643.
85. Morrow JD, Roberts LJ II. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res. 1997;36:1–21.[Medline] [Order article via Infotrieve]
86. Harrison-Bernard LM, Raij L. Post-ovariectomy hypertension is linked to upregulation of renal angiotensin II type I (AT1) receptors and increased salt-sensitivity. Hypertension. 1999;34:36. Abstract.
87. Raij L, Jaimes E, Hayakawa H. Development of post-ovariectomy hypertension is linked to salt sensitivity. Hypertension. 1998;32:601. Abstract.
88.
Nickenig G,
Baumer AT, Grohe C, Kahlert S, Strehlow K, Rosenkranz S, Stablein A,
Beckers F, Smits JFM, Daemen MJAP, Vetter H, Bohm M. Estrogen modulates
AT1 receptor gene expression in vitro and in vivo.
Circulation. 1998;97:2197–2201.
89. Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest. 1997;100:264–269.[Medline] [Order article via Infotrieve]
90. Miller JA, Anacta LA, Cattran C. Impact of gender on the renal response to angiotensin II. Kidney Int. 1999;55:278–285.[Medline] [Order article via Infotrieve]
91. Schunkert H, Hense HW, Andus T, Reigger GA, Straub RH. Relation between dehydroepiandrosterone sulfate and blood pressure levels in a population-based sample. Am J Hypertens. 1999;12:1140–1143.[Medline] [Order article via Infotrieve]
92. Kau MM, Lo MJ, Wang SW, Tsai SC, Chen JJ, Chiao YC, Yeh JY, Lin H, Shum AY, Fang VS, Ho LT, Wang PS. Inhibition of aldosterone production by testosterone in male rats. Metabolism. 1999;48:1108–1114. [Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  J. Song, K. M. Eyster, C. K. Kost Jr, B. Kjellsen, and D. S. Martin Involvement of protein kinase C-CPI-17 in androgen modulation of angiotensin II-renal vasoconstriction Cardiovasc Res, October 23, 2009; (2009) cvp326v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Desjardins, A. Pourdjabbar, A. Quan, H. Leong-Poi, K. Teichert-Kuliszewska, S. Verma, and T. G. Parker Lack of S100A1 in mice confers a gender-dependent hypertensive phenotype and increased mortality after myocardial infarction Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1457 - H1465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Palomba, A. Falbo, F. Zullo, and F. Orio Jr. Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review Endocr. Rev., February 1, 2009; 30(1): 1 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Nakano and D. M. Pollock Contribution of Endothelin A Receptors in Endothelin 1-Dependent Natriuresis in Female Rats Hypertension, February 1, 2009; 53(2): 324 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Saez, V. Reverte, F. Salazar, M. T. Castells, M. T. Llinas, and F. J. Salazar Hypertension and Sex Differences in the Age-Related Renal Changes When Cyclooxygenase-2 Activity Is Reduced During Nephrogenesis Hypertension, February 1, 2009; 53(2): 331 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Gilbert and M. J. Nijland Sex differences in the developmental origins of hypertension and cardiorenal disease Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2008; 295(6): R1941 - R1952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, F. Rao, J. L. Rodriguez-Flores, M. Mahata, M. M. Fung, M. Stridsberg, S. M. Vaingankar, G. Wen, R. M. Salem, M. Das, et al. Naturally Occurring Human Genetic Variation in the 3'-Untranslated Region of the Secretory Protein Chromogranin A Is Associated With Autonomic Blood Pressure Regulation and Hypertension in a Sex-Dependent Fashion J. Am. Coll. Cardiol., October 28, 2008; 52(18): 1468 - 1481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Wang, T. A. Milner, R. C. Speth, A. C. Gore, D. Wu, C. Iadecola, and J. P. Pierce Sex differences in angiotensin signaling in bulbospinal neurons in the rat rostral ventrolateral medulla Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2008; 295(4): R1149 - R1157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. L. Dampney Is the RVLM a key site for sex-related differences in blood pressure regulation? Focus on "Sex differences in angiotensin signaling in bulbospinal neurons in the rat rostral ventrolateral medulla," by Wang et al. Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2008; 295(4): R1147 - R1148. [Full Text] [PDF]
|
|
|
|
|
|
K. Sandberg and H. Ji Why Can't a Woman Be More Like a Man?: Is the Angiotensin Type 2 Receptor to Blame or to Thank? Hypertension, October 1, 2008; 52(4): 615 - 617. [Full Text] [PDF]
|
|
|
|
|
|
A. Lopez-Ruiz, J. Sartori-Valinotti, L. L. Yanes, R. Iliescu, and J. F. Reckelhoff Sex differences in control of blood pressure: role of oxidative stress in hypertension in females Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H466 - H474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Cattran, H. N. Reich, H. J. Beanlands, J. A. Miller, J. W. Scholey, S. Troyanov, and for the Genes, Gender and Glomerulonephritis Group The impact of sex in primary glomerulonephritis Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2247 - 2253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Pendergrass, N. T. Pirro, B. M. Westwood, C. M. Ferrario, K. B. Brosnihan, and M. C. Chappell Sex differences in circulating and renal angiotensins of hypertensive mRen(2).Lewis but not normotensive Lewis rats Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H10 - H20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. B. Ojeda, D. Grigore, and B. T. Alexander Developmental Programming of Hypertension: Insight From Animal Models of Nutritional Manipulation Hypertension, July 1, 2008; 52(1): 44 - 50. [Full Text] [PDF]
|
|
|
|
|
|
F. Salazar, V. Reverte, F. Saez, A. Loria, M. T. Llinas, and F. J. Salazar Age- and Sodium-Sensitive Hypertension and Sex-Dependent Renal Changes in Rats With a Reduced Nephron Number Hypertension, April 1, 2008; 51(4): 1184 - 1189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Ong, A. W.K. Tso, K. S.L. Lam, and B. M.Y. Cheung Gender Difference in Blood Pressure Control and Cardiovascular Risk Factors in Americans With Diagnosed Hypertension Hypertension, April 1, 2008; 51(4): 1142 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Mattson, M. R. Dwinell, A. S. Greene, A. E. Kwitek, R. J. Roman, A. W. Cowley Jr., and H. J. Jacob Chromosomal mapping of the genetic basis of hypertension and renal disease in FHH rats Am J Physiol Renal Physiol, December 1, 2007; 293(6): F1905 - F1914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Ramirez-Lorca, A. Grilo, M. T. Martinez-Larrad, L. Manzano, F. J. Serrano-Hernando, F. J. Moron, V. Perez-Gonzalez, J. L. Gonzalez-Sanchez, J. Fresneda, R. Fernandez-Parrilla, et al. Sex and Body Mass Index Specific Regulation of Blood Pressure by CYP19A1 Gene Variants Hypertension, November 1, 2007; 50(5): 884 - 890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Rigsby, A. E. Burch, S. Ogbi, D. M. Pollock, and A. M. Dorrance Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1754 - R1763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. B. Ojeda, D. Grigore, E. B. Robertson, and B. T. Alexander Estrogen Protects Against Increased Blood Pressure in Postpubertal Female Growth Restricted Offspring Hypertension, October 1, 2007; 50(4): 679 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Maric Mechanisms of Fetal Programming of Adult Hypertension: Role of Sex Hormones Hypertension, October 1, 2007; 50(4): 605 - 606. [Full Text] [PDF]
|
|
|
|
|
|
A. Loria, V. Reverte, F. Salazar, F. Saez, M. T. Llinas, and F. J. Salazar Changes in renal hemodynamics and excretory function induced by a reduction of ANG II effects during renal development Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R695 - R700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Loria, V. Reverte, F. Salazar, F. Saez, M. T. Llinas, and F. J. Salazar Sex and age differences of renal function in rats with reduced ANG II activity during the nephrogenic period Am J Physiol Renal Physiol, August 1, 2007; 293(2): F506 - F510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ji, W. Zheng, C. Falconetti, D. M. Roesch, S. E. Mulroney, and K. Sandberg 17beta-Estradiol deficiency reduces potassium excretion in an angiotensin type 1 receptor-dependent manner Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H17 - H22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Roman and J. H. Lombard Does 20-Hydroxyeicosatetraenoic Acid Contribute to Sex Differences in Cardiovascular Risk by Increasing Oxidative Stress? Hypertension, July 1, 2007; 50(1): 37 - 38. [Full Text] [PDF]
|
|
|
|
|
|
H. Singh, J. Cheng, H. Deng, R. Kemp, T. Ishizuka, A. Nasjletti, and M. L. Schwartzman Vascular Cytochrome P450 4A Expression and 20-Hydroxyeicosatetraenoic Acid Synthesis Contribute to Endothelial Dysfunction in Androgen-Induced Hypertension Hypertension, July 1, 2007; 50(1): 123 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-J. Chen, W.-S. Yang, J.-H. Yang, C.-L. Chen, H.-N. Ho, and Y.-S. Yang Relationship Between Androgen Levels and Blood Pressure in Young Women With Polycystic Ovary Syndrome Hypertension, June 1, 2007; 49(6): 1442 - 1447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Reckelhoff Polycystic Ovary Syndrome: Androgens and Hypertension Hypertension, June 1, 2007; 49(6): 1220 - 1221. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Alonso-Alvarez, S. Bertrand, B. Faivre, O. Chastel, and G. Sorci Testosterone and oxidative stress: the oxidation handicap hypothesis Proc R Soc B, March 22, 2007; 274(1611): 819 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Pilote, K. Dasgupta, V. Guru, K. H. Humphries, J. McGrath, C. Norris, D. Rabi, J. Tremblay, A. Alamian, T. Barnett, et al. A comprehensive view of sex-specific issues related to cardiovascular disease Can. Med. Assoc. J., March 13, 2007; 176(6): S1 - S44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. F. Deschepper and B. Llamas Hypertensive Cardiac Remodeling in Males and Females: From the Bench to the Bedside Hypertension, March 1, 2007; 49(3): 401 - 407. [Full Text] [PDF]
|
|
|
|
|
|
N. B. Ojeda, D. Grigore, L. L. Yanes, R. Iliescu, E. B. Robertson, H. Zhang, and B. T. Alexander Testosterone contributes to marked elevations in mean arterial pressure in adult male intrauterine growth restricted offspring Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R758 - R763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Yamaleyeva, P. E. Gallagher, S. Vinsant, and M. C. Chappell Discoordinate regulation of renal nitric oxide synthase isoforms in ovariectomized mRen2.Lewis rats Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R819 - R826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Maduwegedera, M. M. Kett, R. L. Flower, G. W. Lambert, J. F. Bertram, E. M. Wintour, and K. M. Denton Sex differences in postnatal growth and renal development in offspring of rabbit mothers with chronic secondary hypertension Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2007; 292(2): R706 - R714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Vargas, J. M. Moreno, R. Wangensteen, I. Rodriguez-Gomez, and J. Garcia-Estan The endocrine system in chronic nitric oxide deficiency Eur. J. Endocrinol., January 1, 2007; 156(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Fantin, A. Mattocks, C. J. Bulpitt, W. Banya, and C. Rajkumar Is augmentation index a good measure of vascular stiffness in the elderly? Age Ageing, January 1, 2007; 36(1): 43 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Song, C. K. Kost Jr., and D. S. Martin Androgens potentiate renal vascular responses to angiotensin II via amplification of the Rho kinase signaling pathway Cardiovasc Res, December 1, 2006; 72(3): 456 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. B. Berg Differences in decline in GFR with age between males and females. Reference data on clearances of inulin and PAH in potential kidney donors Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2577 - 2582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nickerson, S. L. Kennedy, J. D. Johnson, and M. Fleshner Sexual dimorphism of the intracellular heat shock protein 72 response J Appl Physiol, August 1, 2006; 101(2): 566 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Franceschini, J. W. MacCluer, H. H.H. Goring, S. A. Cole, K. M. Rose, L. Almasy, V. Diego, S. Laston, E. T. Lee, B. V. Howard, et al. A Quantitative Trait Loci-Specific Gene-by-Sex Interaction on Systolic Blood Pressure Among American Indians: The Strong Heart Family Study Hypertension, August 1, 2006; 48(2): 266 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Song, C. K. Kost Jr., and D. S. Martin Androgens augment renal vascular responses to ANG II in New Zealand genetically hypertensive rats Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2006; 290(6): R1608 - R1615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Reckelhoff, L. L. Yanes, R. Iliescu, L. A. Fortepiani, and J. P. Granger Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease Am J Physiol Renal Physiol, November 1, 2005; 289(5): F941 - F948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Quinkler, I. J. Bujalska, K. Kaur, C. U. Onyimba, S. Buhner, B. Allolio, S. V. Hughes, M. Hewison, and P. M. Stewart Androgen Receptor-Mediated Regulation of the {alpha}-Subunit of the Epithelial Sodium Channel in Human Kidney Hypertension, October 1, 2005; 46(4): 787 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Maric Sex Differences in Cardiovascular Disease and Hypertension: Involvement of the Renin-Angiotensin System Hypertension, September 1, 2005; 46(3): 475 - 476. [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Mendelsohn and R. H. Karas Molecular and Cellular Basis of Cardiovascular Gender Differences Science, June 10, 2005; 308(5728): 1583 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. F. Ba, T. Shimizu, L. Szalay, K. I. Bland, and I. H. Chaudry Gender differences in small intestinal perfusion following trauma hemorrhage: the role of endothelin-1 Am J Physiol Gastrointest Liver Physiol, May 1, 2005; 288(5): G860 - G865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Xue, J. Pamidimukkala, and M. Hay Sex differences in the development of angiotensin II-induced hypertension in conscious mice Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2177 - H2184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Mattson, M. P. Kunert, R. J. Roman, H. J. Jacob, and A. W. Cowley Jr. Substitution of chromosome 1 ameliorates L-NAME hypertension and renal disease in the fawn-hooded hypertensive rat Am J Physiol Renal Physiol, May 1, 2005; 288(5): F1015 - F1022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Sullivan, J. M. Sasser, D. M. Pollock, and J. S. Pollock Sexual Dimorphism in Renal Production of Prostanoids in Spontaneously Hypertensive Rats Hypertension, March 1, 2005; 45(3): 406 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Scotland, M. Madhani, S. Chauhan, S. Moncada, J. Andresen, H. Nilsson, A. J. Hobbs, and A. Ahluwalia Investigation of Vascular Responses in Endothelial Nitric Oxide Synthase/Cyclooxygenase-1 Double-Knockout Mice: Key Role for Endothelium-Derived Hyperpolarizing Factor in the Regulation of Blood Pressure in Vivo Circulation, February 15, 2005; 111(6): 796 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Gainer, A. Bellamine, E. P. Dawson, K. E. Womble, S. W. Grant, Y. Wang, L. A. Cupples, C.-Y. Guo, S. Demissie, C. J. O'Donnell, et al. Functional Variant of CYP4A11 20-Hydroxyeicosatetraenoic Acid Synthase Is Associated With Essential Hypertension Circulation, January 4, 2005; 111(1): 63 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Shankar, G. J. Eckert, C. Saha, W. Tu, and J. H. Pratt The Change in Blood Pressure during Pubertal Growth J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 163 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Head, V. R. Obeyesekere, M. E. Jones, E. R. Simpson, and Z. S. Krozowski Aromatase-Deficient (ArKO) Mice Have Reduced Blood Pressure and Baroreflex Sensitivity Endocrinology, September 1, 2004; 145(9): 4286 - 4291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Quan, S. Chakravarty, J.-K. Chen, J.-C. Chen, S. Loleh, N. Saini, R. C. Harris, J. Capdevila, and R. Quigley Androgens augment proximal tubule transport Am J Physiol Renal Physiol, September 1, 2004; 287(3): F452 - F459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P H Wirtz, R von Kanel, N Rohleder, and J E Fischer Monocyte proinflammatory cytokine release is higher and glucocorticoid sensitivity is lower in middle aged men than in women independent of cardiovascular risk factors Heart, August 1, 2004; 90(8): 853 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Ward, J. Rivera, J. Hodgson, I. B. Puddey, L. J. Beilin, J. R. Falck, and K. D. Croft Urinary 20-Hydroxyeicosatetraenoic Acid Is Associated With Endothelial Dysfunction in Humans Circulation, July 27, 2004; 110(4): 438 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Maric, K. Sandberg, and C. Hinojosa-Laborde Glomerulosclerosis and Tubulointerstitial Fibrosis are Attenuated with 17{beta}-Estradiol in the Aging Dahl Salt Sensitive Rat J. Am. Soc. Nephrol., June 1, 2004; 15(6): 1546 - 1556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sainz, A. Osuna, R. Wangensteen, J. de Dios Luna, I. Rodriguez-Gomez, J. Duarte, J. M. Moreno, and F. Vargas Role of sex, gonadectomy and sex hormones in the development of nitric oxide inhibition-induced hypertension Exp Physiol, March 1, 2004; 89(2): 155 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. F. Ba, Y. Yokoyama, B. Toth, L. W. Rue III, K. I. Bland, and I. H. Chaudry Gender differences in small intestinal endothelial function: inhibitory role of androgens Am J Physiol Gastrointest Liver Physiol, March 1, 2004; 286(3): G452 - G457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Orshal and R. A. Khalil Gender, sex hormones, and vascular tone Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2004; 286(2): R233 - R249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. L. Wynne, J. A. Payne, A. E. Cain, J. F. Reckelhoff, and R. A. Khalil Age-Related Reduction in Estrogen Receptor-Mediated Mechanisms of Vascular Relaxation in Female Spontaneously Hypertensive Rats Hypertension, February 1, 2004; 43(2): 405 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T J. McDonald, K. L. Franko, J. M. Brown, S. L. Jenkins, P. W. Nathanielsz, and M. J. Nijland Betamethasone in the Last Week of Pregnancy Causes Fetal Growth Rtardation but Not Adult Hypertension in Rats Reproductive Sciences, December 1, 2003; 10(8): 469 - 473. [Abstract] [PDF]
|
|
|
|
|
|
J. Titze, R. Lang, C. Ilies, K. H. Schwind, K. A. Kirsch, P. Dietsch, F. C. Luft, and K. F. Hilgers Osmotically inactive skin Na+ storage in rats Am J Physiol Renal Physiol, December 1, 2003; 285(6): F1108 - F1117. [Abstract] [Full Text]
|
|
|
|
|
|
G. A. Harshfield, M. E. Wilson, K. McLeod, C. Hanevold, G. K. Kapuku, L. Mackey, D. Gillis, and L. Edmonds Adiposity Is Related to Gender Differences in Impaired Stress-Induced Pressure Natriuresis Hypertension, December 1, 2003; 42(6): 1082 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Harrison-Bernard, I. H. Schulman, and L. Raij Postovariectomy Hypertension Is Linked to Increased Renal AT1 Receptor and Salt Sensitivity Hypertension, December 1, 2003; 42(6): 1157 - 1163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Javeshghani, R. M. Touyz, M. R. Sairam, A. Virdis, M. F. Neves, and E. L. Schiffrin Attenuated Responses to Angiotensin II in Follitropin Receptor Knockout Mice, a Model of Menopause-Associated Hypertension Hypertension, October 1, 2003; 42(4): 761 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Y. Liu, A. K. Death, and D. J. Handelsman Androgens and Cardiovascular Disease Endocr. Rev., June 1, 2003; 24(3): 313 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Parker A Review of Cardiovascular Disease and Treatment Differences in Women Journal of Pharmacy Practice, June 1, 2003; 16(3): 157 - 163. [Abstract] [PDF]
|
|
|
|
|
|
Z. F. Ba, J. F. Kuebler, L. W. Rue III, K. I. Bland, P. Wang, and I. H. Chaudry Gender dimorphic tissue perfusion response after acute hemorrhage and resuscitation: role of vascular endothelial cell function Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H2162 - H2169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Coatmellec-Taglioni, J.-P. Dausse, Y. Giudicelli, and C. Ribiere Sexual Dimorphism in Cafeteria Diet-Induced Hypertension Is Associated with Gender-Related Difference in Renal Leptin Receptor Down-Regulation J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 362 - 367. [Abstract] [Full Text]
|
|
|
|
|
|
O. Skott Androgen-induced activation of 20-HETE production may contribute to gender differences in blood pressure regulation Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2003; 284(4): R1053 - R1054. [Full Text] [PDF]
|
|
|
|
|
|
K. Nakagawa, J. S. Marji, M. L. Schwartzman, M. R. Waterman, and J. H. Capdevila Androgen-mediated induction of the kidney arachidonate hydroxylases is associated with the development of hypertension Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2003; 284(4): R1055 - R1062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Nash, L. Magder, M. Lustberg, R. W. Sherwin, R. J. Rubin, R. B. Kaufmann, and E. K. Silbergeld Blood Lead, Blood Pressure, and Hypertension in Perimenopausal and Postmenopausal Women JAMA, March 26, 2003; 289(12): 1523 - 1532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Baltatu, C. Cayla, R. Iliescu, D. Andreev, and M. Bader Abolition of End-Organ Damage by Antiandrogen Treatment in Female Hypertensive Transgenic Rats Hypertension, March 1, 2003; 41(3): 830 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kony, M. Zureik, C. Neukirch, B. Leynaert, D. Vervloet, and F. Neukirch Rhinitis Is Associated with Increased Systolic Blood Pressure in Men: A Population-based Study Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 538 - 543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Baltatu, C. Cayla, R. Iliescu, D. Andreev, C. Jordan, and M. Bader Abolition of Hypertension-Induced End-Organ Damage by Androgen Receptor Blockade in Transgenic Rats Harboring the Mouse Ren-2 Gene J. Am. Soc. Nephrol., November 1, 2002; 13(11): 2681 - 2687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Freshour, S. E. Chase, and K. L. Vikstrom Gender differences in cardiac ACE expression are normalized in androgen-deprived male mice Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1997 - H2003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dodic, T. Abouantoun, A. O'Connor, E. M. Wintour, and K. M. Moritz Programming Effects of Short Prenatal Exposure to Dexamethasone in Sheep Hypertension, November 1, 2002; 40(5): 729 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fischer, A. Baessler, and H. Schunkert Renin angiotensin system and gender differences in the cardiovascular system Cardiovasc Res, February 15, 2002; 53(3): 672 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Dubey, S. Oparil, B. Imthurn, and E. K. Jackson Sex hormones and hypertension Cardiovasc Res, February 15, 2002; 53(3): 688 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Charchar, M. Tomaszewski, S. Padmanabhan, B. Lacka, M. N. Upton, G. C. Inglis, N. H. Anderson, A. McConnachie, E. Zukowska-Szczechowska, W. Grzeszczak, et al. The Y Chromosome Effect on Blood Pressure in Two European Populations Hypertension, February 1, 2002; 39(2): 353 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Roberts, N. D. Vaziri, and R. J. Barnard Protective effects of estrogen on gender-specific development of diet-induced hypertension J Appl Physiol, November 1, 2001; 91(5): 2005 - 2009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ranade, K.-D. Wu, C.-M. Hwu, C.-T. Ting, D. Pei, R. Pesich, J. Hebert, Y.-D. I. Chen, R. Pratt, R. Olshen, et al. Genetic variation in the human urea transporter-2 is associated with variation in blood pressure Hum. Mol. Genet., September 1, 2001; 10(19): 2157 - 2164. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||